Anxiety DisordersDepressive DisordersMajor Depressive Disorder (MDD)Safety & Risk ManagementPsilocybin

Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use

In a retrospective survey of psilocybin mushroom users, serotonergic antidepressants (SSRIs, SNRIs) were associated with substantially higher odds of weakened psilocybin effects—about 47% for SSRIs and 55% for SNRIs versus 29% for the non‑serotonergic antidepressant bupropion—and this attenuation persisted for up to three months after discontinuation. Sensitivity analysis excluding fluoxetine did not materially change the post‑discontinuation result.

Authors

  • Roland Griffiths
  • Sandeep Nayak
  • David Yaden

Published

Journal of Psychopharmacology
individual Study

Abstract

Background

Psilocybin is being studied for depression, but little is known about how it interacts with common antidepressants. Limited data suggest that psilocybin’s effects may be diminished by serotonergic antidepressants acutely and even after a medication washout period.

Aims

To learn the extent to which antidepressants may diminish the effects of psilocybin-containing mushrooms both concurrently and after discontinuation of antidepressants.

Methods

Online retrospective survey of individuals with use of psilocybin mushrooms (1) with an antidepressant and/or (2) within 2 years of discontinuing an antidepressant. Participants who took mushrooms with an antidepressant and either took the same dose pre-antidepressant or took the same dose with other people not on antidepressant reported the strength of drug effects relative to their expectation. Participants who took mushrooms following discontinuation of an antidepressant also reported the presence of weakened effects.

Results

In reports ( n = 611) of taking mushrooms with an antidepressant, probabilities [95% CI] of weaker than expected drug effects were 0.47 [0.41–0.54] (selective serotonergic reuptake inhibitors, SSRIs), 0.55 [0.44–0.67] (serotonin norepinephrine reuptake inhibitors, SNRIs) and 0.29 [0.2–0.39] (bupropion). Following SSRI/SNRI discontinuation ( n = 1,542 reports), the probability of reduced drug effects was not significantly different from the earliest post-discontinuation timepoint (within 1 week) until 3–6 months, probability = 0.3 [0.20–0.46], p = 0.001. A sensitivity analysis found that removing responses involving fluoxetine, which has an especially long half-life, did not significantly alter this result.

Conclusions

SSRI/SNRIs appear to weaken psilocybin drug effects relative to a non-serotonergic antidepressant. This dampening effect may last as long as 3 months following antidepressant discontinuation.

Available with Blossom Pro

Research Summary of 'Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use'

Introduction

Gukasyan and colleagues situate the study within growing interest in psilocybin-assisted therapy for major depressive disorder, noting that clinical trials commonly require discontinuation of serotonergic antidepressants prior to psychedelic administration. Prior reports—largely from LSD studies, small clinical samples, and anecdotal sources—have suggested that monoaminergic antidepressants, particularly SSRIs and MAOIs, can attenuate classic psychedelic effects or, conversely, sometimes potentiate them depending on the drug class. There is also theoretical concern about interactions such as serotonin syndrome, but empirical data on psilocybin specifically are limited and mixed. The study therefore aimed to quantify two practical questions in a large naturalistic sample: (1) whether taking an antidepressant concurrent with psilocybin-containing mushrooms is associated with reduced subjective drug intensity, and (2) whether any reduction in subjective intensity persists after discontinuation of antidepressants and for how long. The investigators also collected data on self-reported adverse events, including possible serotonin syndrome. The work is a retrospective online survey intended to capture naturalistic experiences across a broad population of mushroom users with recent or concurrent antidepressant exposure.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Study Details

References (14)

Papers cited by this study that are also in Blossom

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)

656 cited
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up

Davis, A. K., Streeter Barrett, F., Cosimano, M. P. et al. · Journal of Psychopharmacology (2022)

306 cited
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels

Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)

Serotonin toxicity of serotonergic psychedelics

Malcolm, B., Thomas, K. · Psychopharmacology (2021)

Hallucinogens

Nichols, D. E. · Pharmacology and Therapeutics (2004)

Show all 14 references
Psychedelics

Nichols, D. E. · Pharmacological Reviews (2016)

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens

Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)

Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression

Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)

Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review

Sarparast, A., Thomas, K., Malcolm, B. et al. · Psychopharmacology (2022)

Cited By (11)

Papers in Blossom that reference this study

Trip killers: Addressing a critical knowledge gap in psychedelic research

O’Mahony, B., Harrington, C., Harkin, A. et al. · Journal of Psychopharmacology (2026)

Roland R. Griffiths, psychopharmacology pioneer: Abuse liability, alcohol, nicotine, caffeine, benzodiazepines, and psychedelics

Henningfield, J. E., Barrett, F. S., Evans, S. M. et al. · Journal of Psychopharmacology (2026)

1 cited
Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial

Becker, A. M., Humbert-Droz, M., Mueller, L. et al. · Clinical Pharmacology and Therapeutics (2025)

The Impact of Antidepressant Discontinuation Prior to Treatment with Psilocybin for Treatment-Resistant Depression

Marwood, L., Croal, M., Mistry, S. et al. · Journal of Psychiatric Research (2024)

Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression

Erritzoe, D., Barba, T., Spriggs, M. J. et al. · Journal of Psychopharmacology (2024)

17 cited
Drug-drug interactions involving classic psychedelics: A systematic review

Halman, A., Kong, G., Sarris, J. et al. · Journal of Psychopharmacology (2023)

40 cited
Show all 11 papers
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication

Goodwin, G. M., Croal, M., Feifel, D. et al. · Neuropharmacology (2023)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.